12. International EBHC Symposium 2017
HTA: evidence and value in decision-making paradigm
11-12 grudnia 2017 | Kraków
12. International EBHC Symposium 2017
HTA: evidence and value in decision-making paradigm
11-12 grudnia 2017 | Kraków
Final Programme 2017The Symposium took place in Krakow on December 11th and 12th, 2017 in Park Inn Hotel. Park Inn.
Evidence-Based Health Care is becoming a dominant direction for development of health care systems around the world. At the same time, thanks to greater awareness and increasing problems with interpreting results of studies and reviews, basic questions tend to be asked again. After so many years of EBHC development, we pose the question: what is evidence, anyway? We are searching for answers by starting with a single patient (e.g. in the case of rare diseases) and are going up to the level of the entire system – with emphasis on what values and effects we want to achieve.
This edition of our Symposium was intended as a starting point for a discussion on solutions created both in Poland and elsewhere in the world.
Currently, many countries are either analysing phenomena or are already taking actions in areas which we discuss in our sessions:
- Developing value-based health care systems,
- Changing our approach towards obtaining marketing authorisations for drugs based on adaptive pathways; challenges faced by payers in Europe,
- Comprehensiveness and integration of care in the health care system,
- Introducing new medical devices and methods of their financing,
- Clinical guidelines – how they are created, implemented and how do they impact the system,
- The situation and role of rare diseases – including in particular the active attitude of patients and the solutions they prefer.
The market of medicinal products, medical devices and all health services is becoming more and more complicated. In this multilevel structure we encounter both cooperation and competition, and conflicts of interest are not always easy to identify. It seems obvious that the primary objective of health care should be meeting the health needs of the society, which can be done by way of prophylaxis, treatment and monitoring. Each country searches for optimal solutions which would keep up with the ever-changing surroundings and possibilities (and costs) brought about by new solutions.
The aim of this Symposium was to ask: what should the shape of the system be? how should it be financed? – and most of all: what should serve as the basis for its evaluation: costs, effects, values, or political objectives? We will also attempt to find an answer to these questions together. Furthermore, we will consider whether these questions can be used as a long-term indicator for the correct direction of development and when should they be adjusted?
Partners
12. International EBHC Symposium 2017
HTA: evidence and value in decision-making paradigm
11-12 grudnia 2017 | Kraków
12. International EBHC Symposium 2017
HTA: evidence and value in decision-making paradigm
11-12 grudnia 2017 | Kraków
A hand-picked panel of experts from Poland and other countries will present the results of their studies and will suggest proposals of solutions in 6 sessions:
- Directions of changes in health care systems (fee free session)
- Adapt or not to Adapt? Adaptive Pathways: a lifecycle approach in a sustainable way (fee free session)
- New solutions in rare diseases
- Patient care integration
- Evidence – synthesis and translation
- Is it necessary to regulate medical devices in the healthcare system?
Przyjęta formuła Sympozjum zakładała dłuższy czas na dyskusję z wybitnymi ekspertami zagranicznymi, co umożliwiło uczestnikom skorzystanie z ich wiedzy w szerszym zakresie niż ma to zazwyczaj miejsce w ramach tego rodzaju spotkań.
Session 1. Directions of change in health care systems
Representatives of the Polish and Belgian Ministries of Health have been invited to take part in the opening session. They will present their strategic goals and changes planned for the months and years to come. Belgium was one of the first countries in Europe to introduce a value-based systems several years back, therefore we are counting on honest reflections and first-hand experience.
Due to its exceptional educational value, the participation in the first two sessions will be free of charge. This way we want to encourage those who cannot take part in the entire Symposium – students and fellow scientists – to participate in the event. It is an opportunity to establish direct contact with representatives of the Polish Ministry of Health and The Agency for Health Technology Assessment and Tariff System (AOTMiT). We hope for a lively discussion after the session. top
Session 2. Adapt or not to Adapt? Adaptive Pathways: a lifecycle approach in a sustainable way
A broad group of stakeholders has been invited to participate in the session on adaptive pathways, including patients, representatives of registration offices and the European Medicines Agency in order to discuss problems and challenges faced by payers. top
Session 3. New solutions in rare diseases
The Symposium also has the goal of supporting and educating the invited patient associations dealing with rare diseases. The session on rare diseases will present methods for measuring patients’ preferences and practical solutions developed in France which ensure comprehensiveness of treatment. Patients’ organizations were also invited to participate in the session, thanks to which the discussion has a chance to raise all aspects and problems related to the availability of diagnosis and treatment of rare diseases. top
Session 4. Patient care integration
We are convinced that, despite many years of reform, it is necessary to continue the discussion on financing of services. Especially in view of such dynamic positive changes regarding the network of hospitals, medical devices, or integrated patient care. We hope that Polish and foreign examples of system solutions presented during the Symposium will constitute good starting points for an exchange of opinions. top
Session 5. Evidence – synthesis and translation
The session on synthesis of evidence and creating guidelines will present the latest concepts. This session will demonstrate the latest Polish and Czech solutions and the years-long engagement of Cochrane, an international organisation, in the creation of credible methodology for systematic reviews. top
Session 6. Is it necessary to regulate medical devices in the healthcare system?
In the session on medical devices, we will hold a panel discussion between representatives of the pharmaceutical industry, the public payer, experts in health care and clinicians. top
12. International EBHC Symposium 2017
HTA: evidence and value in decision-making paradigm
11-12 grudnia 2017 | Kraków
12. International EBHC Symposium 2017
HTA: evidence and value in decision-making paradigm
11-12 grudnia 2017 | Kraków
Prezentacje:
- Value Based Reimbursement in Belgium and BeNeLuxA /
4,8 MB // Francis Arickx, Belgium - Ocena błędu systematycznego w syntezie danych naukowych / 8,9 MB // Małgorzata Bała, Poland
- A perspective from 12 years of strategy for rare diseases in France: what’s new? what’s inspirational? / 2,8 MB // Myriam de Chalendar, France
- Rehabilitacja lecznicza. Potencjalne kierunki zmian systemowych / 0,4 MB // Dominik Dziurda, Poland
- Joint Curriculum MSc in Health Technology Assessment – 2-year program in English at Medical University of Warsaw / 0,2 MB // Tomasz Hermanowski1 (Poland), Alan Haycox (UK), Anna Zawada (Poland)
- Project of national centre for Clinical Practice Guidelines in the Czech Republic. Data from Systematic Reviews in development of Clinical Practice Guidelines / 15,6 MB // Miloslav Klugar, Czech Republic
- The significance of endpoint selection for clinical trials / 1,8 MB // Anna Kordecka, Poland
- Program pilotażowy psychiatrii środowiskowej w ramach Narodowego Programu Ochrony Zdrowia Psychicznego – Centra Zdrowia Psychicznego / 0,7 MB // Zbigniew Król, Poland
- Wspólnoty pacjentów jako wspólnoty wiedzy / 2,7 MB // Maria Libura, Poland
- Projekt ustawy RWM o refundacji wyrobów medycznych / 1,0 MB // Krzysztof Łanda, Poland
- Financing of orphan drugs in Europe – preliminary results / 0,4 MB // Robert Plisko, Poland
- ADAPT SMART – Regulatory perspectives / 3,8 MB // Csilla Pozsgay, Hungary
- Adaptive Pathways: a balanced approach to life-cycle and patient perspectives / 1,9 MB // Michał Rataj, Poland
- Expenses we do not notice – an indirect cost analysis on the example of chronic hand eczema / 4,4 MB // Paulina Rolska, Poland
- Foundation for Good Legislation / 0,3 MB // Katarzyna Sabiłło, Poland
- Value assessment of orphan drugs for rare diseases / 4,3 MB // Steven Simoens, Belgium
- Value-Based Health Care – an industry perspective / 0,7 MB // Mitchell Sugarman, USA
- Międzyresortowa, koordynowana opieka nad pacjentem. Organizacyjne rozwiązania pilotażowe / 2,7 MB // Andrzej Śliwczyński, Poland
- Wartość jakości w systemie ochrony zdrowia / 5,9 MB // Roman Topór-Mądry, Poland
- Nowe zasady refundacji wyrobów medycznych / 1,1 MB // Ewa Warmińska, Poland
- Development, adaptation and adoption of clinical practice guidelines: application of the GRADE Evidence-to-Decision framework / 11,8 MB // Wojtek Wiercioch, Canada
English (UK) 
Polski